近几十年来，骨肉瘤一直是最常见的恶性肿瘤。在免疫治疗中，抗原加工和呈递（APP）是一个重要而关键的因素。然而，对骨肉瘤中APP的具体功能和致病过程的研究尚未进行。我们将骨肉瘤患者按照APP相关基因进行分组，并使用机器学习建立了APP相关评分。我们深入研究了评分的预后相关性、突变特征、免疫学方面和药物预测性能。我们还深入调查了BNIP3的预后效用、免疫特征、药物预测效果和免疫治疗预测。细胞计数试剂盒-8、Transwell和5-乙炔基-2-脱氧尿苷（EdU）的研究表明BNIP3是一种骨肉瘤肿瘤增速器。BNIP3基因可能促进巨噬细胞迁移。APP相关评分显示有潜力用于临床应用。预计进一步的体外和体内研究将确认BNIP3在骨肉瘤中的肿瘤发生和免疫过程。© 2023 John Wiley & Sons Ltd.

In recent decades, osteosarcoma has remained the most prevalent kind of malignant tumor. An important and crucial factor in immunotherapy is antigen processing and presentation (APP). The specific functions and pathogenic processes of APP in osteosarcoma have not, however, been studied.Patients with osteosarcoma were divided into groups using APP-related genes. Machine learning was used to further build the APP-related score. Investigated in-depth were the prognostic relevance of the score, mutation features, immunological aspects, and pharmacological prediction performance. Investigations of the prognostic utility, immunological traits, drug prediction effectiveness and immunotherapy prediction of BNIP3 were performed in-depth.Investigations by cell counting kit-8, Transwell and 5-ethynyl-2-deoxyuridine (EdU) demonstrated that BNIP3 is an osteosarcoma tumor accelerator. The osteosarcoma gene BNIP3 may promote macrophage migration. The APP-related score shows potential for clinical use.It was anticipated that more in vitro and in vivo studies would confirm BNIP3's tumorigenic and immunogenic processes in osteosarcoma.© 2023 John Wiley & Sons Ltd.